Oak Longevity Review

Oak has the paperwork you want to see: a named entity in Oak Longevity Holdings Corp., care delivered through NVP Medical Group, P.A., published terms and reachable contact details. And critically, our search of the FDA warning letter database returned nothing against Oak. Given the FDA has issued dozens of letters to telehealth firms for implying their compounded GLP-1s are equivalent to approved drugs, a clean record is a real point in Oak's favour.

Be sceptical of the review landscape though. Searching Oak surfaces confident “2026 updated” reviews hosted on newswire press-release servicesand on affiliate-operated sites — one rates it 4.8/5 after “30+ hours of research”. Those are marketing assets, not independent assessment. Genuine, verifiable customer-feedback volume for Oak is thin, which is the usual position for a newer platform and simply means less to go on.

What to check before you buy

• •Confirm the package length attached to your quoted price — $130 is not the one-month rate
• •Read the guarantee terms; it reportedly only refunds you if a physician declines to prescribe
• •Ask which compounding pharmacy fills your prescription, and whether it is 503A or 503B
• •Ask what clinical basis supports compounding for you, now that neither drug is in shortage
• •Check what happens if you stop mid-way through a 3-month package

How much does Oak actually cost?

Less than most, but more than the headline. Oak advertises from $130/month for compounded semaglutide and $199/month for compounded tirzepatide, with free shipping and no membership fee. Those figures are tied to multi-month packages. For a single month, reported in-funnel pricing is around $235 for semaglutide and $285 for tirzepatide — a substantial gap from the marketing. A promo code (OAKNEW50) has been offering $50 off the first month. Before paying, confirm which package length your quoted price assumes.

What does Oak's money-back guarantee actually cover?

Read this one carefully, because it is not what most people assume. Oak's guarantee reportedly triggers only if a physician declines to approve your prescription — in other words, you get your money back if you were never eligible to be a customer. It is not a satisfaction guarantee, and it does not cover you if you start treatment and decide it is not working or cannot tolerate the side effects. That is a meaningfully weaker protection than a genuine refund window, and worth contrasting with providers offering 30- or 60-day money-back terms.

Is Oak legitimate?

The structural signals are reasonable. There is a named corporate entity, Oak Longevity Holdings Corp., an identified medical group in NVP Medical Group, P.A., published terms of use and listed contact details — this is not an anonymous storefront. Importantly, we checked the FDA's warning letter database and found no letter against Oak, which matters in a category where the FDA has written to dozens of telehealth companies over compounded GLP-1 marketing. The weakness is independent evidence of service quality: the enthusiastic reviews that dominate search results are largely distributed press releases and affiliate-operated sites, not journalism or verifiable customer feedback at volume.

Does Oak offer brand-name Ozempic or Wegovy?

No. Oak's offering is compounded semaglutide and tirzepatide. Compounded medications are prepared by licensed compounding pharmacies, are not FDA-approved, and are not evaluated by the FDA for safety, effectiveness or quality. They share an active ingredient with the branded products but are not equivalent to them. If you want brand-name FDA-approved medication, or insurance coverage, look at the providers on this site that offer insurance navigation instead.

Can I still get compounded GLP-1s in 2026?

It is more restricted than it was. Tirzepatide came off the FDA drug shortage list in December 2024 and semaglutide in February 2025, and once a drug is no longer in shortage, pharmacies may not routinely compound what amounts to a copy of the commercial product. Patient-specific compounding for a documented clinical need remains lawful, and in April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk substances list, tightening things further. Ask Oak directly what clinical basis supports compounding in your case — a provider that cannot answer that clearly is worth avoiding.

What are the side effects?

The common ones are gastrointestinal: nausea, vomiting, diarrhoea and constipation, usually worst during dose escalation. More serious risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease and, in animal studies, thyroid C-cell tumours — these medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Do not use them if pregnant or trying to conceive. This is informational only; discuss your own history with the prescribing clinician.